Patients with advanced non-small cell lung cancer (NSCLC) who harbor susceptible
epidermal growth factor receptor (EGFR) mutations and are treated with EGFR tyrosine …

Background. Univariate analyses from several randomized phase III trials seemed to
suggest ever-smokers with advanced mutated epidermal growth factor receptor (EGFRm) …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …

Background The strong association between smoking history and the presence of epidermal
growth factor receptor (EGFR) mutations has been proven in non–small-cell lung cancer …

Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

Objective: The objective of this study was to perform a meta-analysis comparing the
efficiency of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with …

Aim: To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line
treatment in patients with locally advanced or metastatic non-small-cell lung cancer …

Background: EGFR-TKI (tyrosine kinase inhibitor) monotherapy has become the first-line
treatment option for patients with EGFR-mutated non-small cell lung cancer (NSCLC) …

The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …

Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …